Skip to Content
  • Revenues ($M)$10,764
  • Revenue Percent Change10.9%
  • Profits ($M)$3,547
  • Profits Percent Change20.9%
  • Assets ($M)$19,505
  • Employees7,350
  • Market Value — as of March 31, 2016 ($M)$56,925
  • Previous Rank298
  • Morning Consult Brand Index
    C-

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Michel Vounatsos
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Cambridge, MA
Websitehttp://www.biogen.com
Years on Fortune 500 List7
Employees7,350

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$10,76410.9%
Profits ($M)$3,54720.9%
Assets ($M)$19,505-
Total Stockholder Equity ($M)$9,373-
Market Value — as of March 31, 2016 ($M)$56,925-

Profit Ratios

Profit as % of Revenues33%
Profits as % of Assets18.2%
Profits as % of Stockholder Equity37.8%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)15.34
EPS % Change (from 2014)24%
EPS % Change (5 year annual rate)31.2%
EPS % Change (10 year annual rate)41.7%

Total Return

Total Return to Investors (2015)-9.8%
Total Return to Investors (5 year, annualized)35.5%
Total Return to Investors (10 year, annualized)21.1%